Postpartum depression

© Rayp808 |

FDA approved drug for treating postpartum depression comes with hefty price

March 20, 2019 - 10:59 am

NEW YORK (1010 WINS) -- There's some good news for struggling new mothers.

The Food and Drug Administration has approved the first drug for treating postpartum depression.  

On Tuesday, the FDA announced its approval for the intravenous infusion of the drug Brexanolone, which will be sold as Zulresso.

PPD can affect women during pregnancy or after childbirth. Symptoms may include sadness, anxiety, irritability, withdrawing from friends or family, having trouble bonding with her baby and thinking about harming herself or more rarely, her baby. Without proper screening, up to half of PPD cases may go undiagnosed.

Dr. Jennifer Ashton says postpartum depression affects one-in-nine new mothers. 

"Postpartum is life-threatening -- it's not a matter of being tired or "hormonal," Ashton said. "So to have a first drug of its kind FDA approved for the treatment of PPD is massive."

Also massive: The price for the infusion. It runs anywhere from $25,000 to $35,000 per treatment.

Like 1010 WINS on Facebook and follow @1010WINS on Twitter to get breaking news, traffic, and weather for New York City.